{"id":"https://openalex.org/W1980628210","doi":"https://doi.org/10.1186/1479-5876-10-236","title":"Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion","display_name":"Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion","publication_year":2012,"publication_date":"2012-11-21","ids":{"openalex":"https://openalex.org/W1980628210","doi":"https://doi.org/10.1186/1479-5876-10-236","mag":"1980628210","pmid":"https://pubmed.ncbi.nlm.nih.gov/23171508","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/3543342"},"language":"en","primary_location":{"id":"doi:10.1186/1479-5876-10-236","doi":"https://doi.org/10.1186/1479-5876-10-236","is_oa":true,"landing_page_url":"https://doi.org/10.1186/1479-5876-10-236","pdf_url":"https://translational-medicine.biomedcentral.com/counter/pdf/10.1186/1479-5876-10-236","source":{"id":"https://openalex.org/S142026636","display_name":"Journal of Translational Medicine","issn_l":"1479-5876","issn":["1479-5876"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["anvur-scientific","cwts-core","doaj","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-2","oarl","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320256","host_organization_name":"BioMed Central","host_organization_lineage":["https://openalex.org/P4310320256","https://openalex.org/P4310319965"],"host_organization_lineage_names":["BioMed Central","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Translational Medicine","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://translational-medicine.biomedcentral.com/counter/pdf/10.1186/1479-5876-10-236","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5083745558","display_name":"Antoni Ribas","orcid":"https://orcid.org/0000-0003-3669-8458","observed_orcids":["https://orcid.org/0000-0003-3669-8458"]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]},{"id":"https://openalex.org/I4390039293","display_name":"UCLA Jonsson Comprehensive Cancer Center","ror":"https://ror.org/0599cs764","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799798094","https://openalex.org/I4390039293"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Antoni Ribas","raw_affiliation_strings":["Division of Hematology-Oncology, 11-934 Factor Building, Jonsson Comprehensive Cancer Center at the University of California Los Angeles, Los Angeles, CA 90095-1782, USA. aribas@mednet.ucla.edu","Division of Hematology-Oncology, 11-934 Factor Building, Jonsson Comprehensive Cancer Center at the University of California Los Angeles, Los Angeles, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology-Oncology, 11-934 Factor Building, Jonsson Comprehensive Cancer Center at the University of California Los Angeles, Los Angeles, CA 90095-1782, USA. aribas@mednet.ucla.edu","institution_ids":["https://openalex.org/I161318765","https://openalex.org/I4390039293"]},{"raw_affiliation_string":"Division of Hematology-Oncology, 11-934 Factor Building, Jonsson Comprehensive Cancer Center at the University of California Los Angeles, Los Angeles, USA","institution_ids":["https://openalex.org/I161318765","https://openalex.org/I4390039293"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086165685","display_name":"Jason Alan Chesney","orcid":"https://orcid.org/0000-0003-0217-8278","observed_orcids":["https://orcid.org/0000-0003-0217-8278"]},"institutions":[{"id":"https://openalex.org/I142740786","display_name":"University of Louisville","ror":"https://ror.org/01ckdn478","country_code":"US","type":"education","lineage":["https://openalex.org/I142740786"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jason A Chesney","raw_affiliation_strings":["James Graham Brown Cancer Center, University of Louisville, Louisville, KY, USA","James Graham Brown Cancer Center, University of Louisville,Louisville,USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"James Graham Brown Cancer Center, University of Louisville, Louisville, KY, USA","institution_ids":["https://openalex.org/I142740786"]},{"raw_affiliation_string":"James Graham Brown Cancer Center, University of Louisville,Louisville,USA","institution_ids":["https://openalex.org/I142740786"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069690249","display_name":"Michael S. Gordon","orcid":"https://orcid.org/0000-0002-7679-9504","observed_orcids":["https://orcid.org/0000-0002-7679-9504"]},"institutions":[{"id":"https://openalex.org/I4210146652","display_name":"Pinnacle Oncology Hematology","ror":"https://ror.org/043rqx383","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210146652"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael S Gordon","raw_affiliation_strings":["Premiere Oncology of Arizona, Scottsdale, AZ, USA","Premiere Oncology of Arizona, Scottsdale, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Premiere Oncology of Arizona, Scottsdale, AZ, USA","institution_ids":["https://openalex.org/I4210146652"]},{"raw_affiliation_string":"Premiere Oncology of Arizona, Scottsdale, USA","institution_ids":["https://openalex.org/I4210146652"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079817843","display_name":"Amy P. Abernethy","orcid":"https://orcid.org/0000-0001-6930-8722","observed_orcids":["https://orcid.org/0000-0001-6930-8722"]},"institutions":[{"id":"https://openalex.org/I170897317","display_name":"Duke University","ror":"https://ror.org/00py81415","country_code":"US","type":"education","lineage":["https://openalex.org/I170897317"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Amy P Abernethy","raw_affiliation_strings":["Duke University, Durham, NC, USA","Duke University, Durham, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Duke University, Durham, NC, USA","institution_ids":["https://openalex.org/I170897317"]},{"raw_affiliation_string":"Duke University, Durham, USA","institution_ids":["https://openalex.org/I170897317"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103165801","display_name":"Theodore F. Logan","orcid":"https://orcid.org/0000-0002-9245-0820","observed_orcids":["https://orcid.org/0000-0002-9245-0820"]},"institutions":[{"id":"https://openalex.org/I4388446366","display_name":"Indiana University Indianapolis","ror":"https://ror.org/03eftgw80","country_code":"US","type":"education","lineage":["https://openalex.org/I4388446366","https://openalex.org/I592451"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Theodore F Logan","raw_affiliation_strings":["Indiana University, Indianapolis, IN, USA","Indiana University - Indianapolis, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Indiana University, Indianapolis, IN, USA","institution_ids":["https://openalex.org/I4388446366"]},{"raw_affiliation_string":"Indiana University - Indianapolis, USA","institution_ids":["https://openalex.org/I4388446366"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056670989","display_name":"David H. Lawson","orcid":"https://orcid.org/0000-0002-9474-8321","observed_orcids":["https://orcid.org/0000-0002-9474-8321"]},"institutions":[{"id":"https://openalex.org/I150468666","display_name":"Emory University","ror":"https://ror.org/03czfpz43","country_code":"US","type":"education","lineage":["https://openalex.org/I150468666"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David H Lawson","raw_affiliation_strings":["Emory University, Atlanta, GA, USA","Emory University, Atlanta, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Emory University, Atlanta, GA, USA","institution_ids":["https://openalex.org/I150468666"]},{"raw_affiliation_string":"Emory University, Atlanta, USA","institution_ids":["https://openalex.org/I150468666"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058013029","display_name":"Bartosz Chmielowksi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]},{"id":"https://openalex.org/I4390039293","display_name":"UCLA Jonsson Comprehensive Cancer Center","ror":"https://ror.org/0599cs764","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799798094","https://openalex.org/I4390039293"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bartosz Chmielowksi","raw_affiliation_strings":["Division of Hematology-Oncology, 11-934 Factor Building, Jonsson Comprehensive Cancer Center at the University of California Los Angeles, Los Angeles, CA, 90095-1782, USA","Division of Hematology-Oncology, 11-934 Factor Building, Jonsson Comprehensive Cancer Center at the University of California Los Angeles, Los Angeles, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology-Oncology, 11-934 Factor Building, Jonsson Comprehensive Cancer Center at the University of California Los Angeles, Los Angeles, CA, 90095-1782, USA","institution_ids":["https://openalex.org/I161318765","https://openalex.org/I4390039293"]},{"raw_affiliation_string":"Division of Hematology-Oncology, 11-934 Factor Building, Jonsson Comprehensive Cancer Center at the University of California Los Angeles, Los Angeles, USA","institution_ids":["https://openalex.org/I161318765","https://openalex.org/I4390039293"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080006341","display_name":"John A. Glaspy","orcid":"https://orcid.org/0000-0002-1800-9076","observed_orcids":["https://orcid.org/0000-0002-1800-9076"]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]},{"id":"https://openalex.org/I4390039293","display_name":"UCLA Jonsson Comprehensive Cancer Center","ror":"https://ror.org/0599cs764","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799798094","https://openalex.org/I4390039293"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John A Glaspy","raw_affiliation_strings":["Division of Hematology-Oncology, 11-934 Factor Building, Jonsson Comprehensive Cancer Center at the University of California Los Angeles, Los Angeles, CA, 90095-1782, USA","Division of Hematology-Oncology, 11-934 Factor Building, Jonsson Comprehensive Cancer Center at the University of California Los Angeles, Los Angeles, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology-Oncology, 11-934 Factor Building, Jonsson Comprehensive Cancer Center at the University of California Los Angeles, Los Angeles, CA, 90095-1782, USA","institution_ids":["https://openalex.org/I161318765","https://openalex.org/I4390039293"]},{"raw_affiliation_string":"Division of Hematology-Oncology, 11-934 Factor Building, Jonsson Comprehensive Cancer Center at the University of California Los Angeles, Los Angeles, USA","institution_ids":["https://openalex.org/I161318765","https://openalex.org/I4390039293"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010628808","display_name":"Karl D. Lewis","orcid":"https://orcid.org/0000-0001-9893-0537","observed_orcids":["https://orcid.org/0000-0001-9893-0537"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Karl Lewis","raw_affiliation_strings":["University of Colorado, Aurora, CO, USA","University Of Colorado, Aurora, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Colorado, Aurora, CO, USA","institution_ids":[]},{"raw_affiliation_string":"University Of Colorado, Aurora, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046444872","display_name":"Bo Huang","orcid":"https://orcid.org/0000-0002-3088-9328","observed_orcids":["https://orcid.org/0000-0002-3088-9328"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bo Huang","raw_affiliation_strings":["Pfizer Inc., Groton, CT, La jolla, CA, USA","Pfizer Inc., Groton, CT, La jolla, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Inc., Groton, CT, La jolla, CA, USA","institution_ids":["https://openalex.org/I180857899"]},{"raw_affiliation_string":"Pfizer Inc., Groton, CT, La jolla, USA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Erjian Wang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Erjian Wang","raw_affiliation_strings":["Pfizer Inc., Groton, CT, La jolla, CA, USA","Pfizer Inc., Groton, CT, La jolla, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Inc., Groton, CT, La jolla, CA, USA","institution_ids":["https://openalex.org/I180857899"]},{"raw_affiliation_string":"Pfizer Inc., Groton, CT, La jolla, USA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109994152","display_name":"Poe\u2010Hirr Hsyu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Poe-Hirr Hsyu","raw_affiliation_strings":["Pfizer Inc., Groton, CT, La jolla, CA, USA","Pfizer Inc., Groton, CT, La jolla, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Inc., Groton, CT, La jolla, CA, USA","institution_ids":["https://openalex.org/I180857899"]},{"raw_affiliation_string":"Pfizer Inc., Groton, CT, La jolla, USA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111774404","display_name":"Jes\u00fas G\u00f3mez-Navarro","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jesus Gomez-Navarro","raw_affiliation_strings":["Millennium-Takeda, Boston, Massachusetts, USA","Pfizer Inc., Groton, CT, La jolla, CA, USA","Millennium-Takeda, Boston, USA","Pfizer Inc., Groton, CT, La jolla, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Millennium-Takeda, Boston, Massachusetts, USA","institution_ids":[]},{"raw_affiliation_string":"Pfizer Inc., Groton, CT, La jolla, CA, USA","institution_ids":["https://openalex.org/I180857899"]},{"raw_affiliation_string":"Millennium-Takeda, Boston, USA","institution_ids":[]},{"raw_affiliation_string":"Pfizer Inc., Groton, CT, La jolla, USA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018664446","display_name":"Diana Gerhardt","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Diana Gerhardt","raw_affiliation_strings":["Pfizer Inc., Groton, CT, La jolla, CA, USA","Pfizer Inc., Groton, CT, La jolla, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Inc., Groton, CT, La jolla, CA, USA","institution_ids":["https://openalex.org/I180857899"]},{"raw_affiliation_string":"Pfizer Inc., Groton, CT, La jolla, USA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031825011","display_name":"Margaret A Marshall","orcid":"https://orcid.org/0000-0002-2019-1444","observed_orcids":["https://orcid.org/0000-0002-2019-1444"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Margaret A Marshall","raw_affiliation_strings":["Pfizer Inc., Groton, CT, La jolla, CA, USA","Pfizer Inc., Groton, CT, La jolla, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Inc., Groton, CT, La jolla, CA, USA","institution_ids":["https://openalex.org/I180857899"]},{"raw_affiliation_string":"Pfizer Inc., Groton, CT, La jolla, USA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5002655892","display_name":"Rene C. Gonzalez","orcid":"https://orcid.org/0000-0002-7435-6208","observed_orcids":["https://orcid.org/0000-0002-7435-6208"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Rene Gonzalez","raw_affiliation_strings":["University of Colorado, Aurora, CO, USA","University Of Colorado, Aurora, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Colorado, Aurora, CO, USA","institution_ids":[]},{"raw_affiliation_string":"University Of Colorado, Aurora, USA","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":8,"corresponding_author_ids":["https://openalex.org/A5083745558"],"corresponding_institution_ids":["https://openalex.org/I161318765","https://openalex.org/I4390039293"],"apc_list":{"value":3890,"currency":"USD","value_usd":3890},"apc_paid":{"value":3890,"currency":"USD","value_usd":3890},"fwci":2.2908,"has_fulltext":true,"cited_by_count":42,"citation_normalized_percentile":{"value":0.88064235,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"10","issue":"1","first_page":"236","last_page":"236"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/tremelimumab","display_name":"tremelimumab","score":1.0},{"id":"https://openalex.org/keywords/ctla-4-blockade","display_name":"CTLA-4 blockade","score":0.8220000267028809},{"id":"https://openalex.org/keywords/metastatic-melanoma","display_name":"metastatic melanoma","score":0.8600000143051147},{"id":"https://openalex.org/keywords/infusion-time-reduction","display_name":"infusion time reduction","score":0.6240000128746033},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.7710000276565552},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.8519999980926514},{"id":"https://openalex.org/keywords/infusion-related-adverse-events","display_name":"infusion-related adverse events","score":0.8479999899864197},{"id":"https://openalex.org/keywords/tumor-response","display_name":"tumor response","score":0.5979999899864197}],"concepts":[{"id":"https://openalex.org/C2778650287","wikidata":"https://www.wikidata.org/wiki/Q7838098","display_name":"Tremelimumab","level":5,"score":0.9909932613372803},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8391655683517456},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.7746136784553528},{"id":"https://openalex.org/C2781433595","wikidata":"https://www.wikidata.org/wiki/Q2459042","display_name":"Ipilimumab","level":4,"score":0.7024058699607849},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.6279908418655396},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.6007159352302551},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.5819122791290283},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.5198271870613098},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.48144835233688354},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.47816330194473267},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4101664423942566},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.3517524003982544},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.17957693338394165}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D003710","descriptor_name":"Demography","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007262","descriptor_name":"Infusions, Intravenous","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000000981","qualifier_name":"diagnostic imaging","is_major_topic":false},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012878","descriptor_name":"Skin Neoplasms","qualifier_ui":"Q000000981","qualifier_name":"diagnostic imaging","is_major_topic":false},{"descriptor_ui":"D012878","descriptor_name":"Skin Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D013997","descriptor_name":"Time Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D049268","descriptor_name":"Positron-Emission Tomography","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D060908","descriptor_name":"CTLA-4 Antigen","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":true},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":6,"locations":[{"id":"doi:10.1186/1479-5876-10-236","doi":"https://doi.org/10.1186/1479-5876-10-236","is_oa":true,"landing_page_url":"https://doi.org/10.1186/1479-5876-10-236","pdf_url":"https://translational-medicine.biomedcentral.com/counter/pdf/10.1186/1479-5876-10-236","source":{"id":"https://openalex.org/S142026636","display_name":"Journal of Translational Medicine","issn_l":"1479-5876","issn":["1479-5876"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["anvur-scientific","cwts-core","doaj","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-2","oarl","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320256","host_organization_name":"BioMed Central","host_organization_lineage":["https://openalex.org/P4310320256","https://openalex.org/P4310319965"],"host_organization_lineage_names":["BioMed Central","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Translational Medicine","raw_type":"journal-article"},{"id":"pmid:23171508","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/23171508","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of translational medicine","raw_type":"Clinical Trial, Phase I"},{"id":"pmh:oai:pubmedcentral.nih.gov:3543342","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3543342/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"J Transl Med","raw_type":"Text"},{"id":"pmh:oai:doaj.org/article:77e605fdeb0e419fa7f1fd10b3d924a9","doi":null,"is_oa":false,"landing_page_url":"https://doaj.org/article/77e605fdeb0e419fa7f1fd10b3d924a9","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Journal of Translational Medicine, Vol 10, Iss 1, p 236 (2012)","raw_type":"article"},{"id":"pmh:oai:escholarship.org/ark:/13030/qt08b3211x","doi":null,"is_oa":false,"landing_page_url":"https://escholarship.org/uc/item/08b3211x","pdf_url":null,"source":{"id":"https://openalex.org/S4306400115","display_name":"eScholarship (California Digital Library)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I2801248553","host_organization_name":"California Digital Library","host_organization_lineage":["https://openalex.org/I2801248553"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Journal of Translational Medicine, vol 10, iss 1","raw_type":"article"},{"id":"pmh:qt08b3211x","doi":null,"is_oa":false,"landing_page_url":"http://www.escholarship.org/uc/item/08b3211x","pdf_url":null,"source":{"id":"https://openalex.org/S4306400115","display_name":"eScholarship (California Digital Library)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I2801248553","host_organization_name":"California Digital Library","host_organization_lineage":["https://openalex.org/I2801248553"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Ribas, Antoni; Chesney, Jason A; Gordon, Michael S; Abernethy, Amy P; Logan, Theodore F; Lawson, David H; \u00c2\u00a0et al.(2012). Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion. Journal of Translational Medicine, 10(1), 236. doi: http://dx.doi.org/10.1186/1479-5876-10-236. Retrieved from: http://www.escholarship.org/uc/item/08b3211x","raw_type":"article"}],"best_oa_location":{"id":"doi:10.1186/1479-5876-10-236","doi":"https://doi.org/10.1186/1479-5876-10-236","is_oa":true,"landing_page_url":"https://doi.org/10.1186/1479-5876-10-236","pdf_url":"https://translational-medicine.biomedcentral.com/counter/pdf/10.1186/1479-5876-10-236","source":{"id":"https://openalex.org/S142026636","display_name":"Journal of Translational Medicine","issn_l":"1479-5876","issn":["1479-5876"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["anvur-scientific","cwts-core","doaj","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-2","oarl","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320256","host_organization_name":"BioMed Central","host_organization_lineage":["https://openalex.org/P4310320256","https://openalex.org/P4310319965"],"host_organization_lineage_names":["BioMed Central","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Translational Medicine","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[{"id":"https://openalex.org/G5986577533","display_name":"Atlanta Clinical and Translational Science Institute (ACTSI) Renewal","funder_award_id":"UL1TR000454","funder_id":"https://openalex.org/F4320332161","funder_display_name":"National Institutes of Health"}],"funders":[{"id":"https://openalex.org/F4320307765","display_name":"Pfizer","ror":"https://ror.org/01xdqrp08"},{"id":"https://openalex.org/F4320332161","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88"},{"id":"https://openalex.org/F4320337472","display_name":"National Center for Advancing Translational Sciences","ror":"https://ror.org/04pw6fb54"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W1980628210.pdf","grobid_xml":"https://content.openalex.org/works/W1980628210.grobid-xml"},"referenced_works_count":14,"referenced_works":["https://openalex.org/W1965494873","https://openalex.org/W2014545440","https://openalex.org/W2034378000","https://openalex.org/W2097995306","https://openalex.org/W2104925898","https://openalex.org/W2116169737","https://openalex.org/W2123363005","https://openalex.org/W2136746908","https://openalex.org/W2139324205","https://openalex.org/W2141579931","https://openalex.org/W2163184777","https://openalex.org/W2164918836","https://openalex.org/W2166626276","https://openalex.org/W2243750606"],"related_works":["https://openalex.org/W2299935477","https://openalex.org/W2141579931","https://openalex.org/W2119342305","https://openalex.org/W2333306575","https://openalex.org/W2256155807","https://openalex.org/W2104925898","https://openalex.org/W2971409995","https://openalex.org/W2139324205","https://openalex.org/W1996865879","https://openalex.org/W2030395337"],"abstract_inverted_index":{"BACKGROUND:":[0],"CTLA4":[1,166],"blocking":[2],"monoclonal":[3],"antibodies":[4],"provide":[5],"a":[6,50,67,87,183],"low":[7],"frequency":[8],"but":[9],"durable":[10],"tumor":[11,145],"responses":[12,146],"in":[13,46,55,127,149],"patients":[14,91,153],"with":[15,32,92,138,141,154,161,165],"metastatic":[16,93,155],"melanoma,":[17,156],"which":[18,157],"led":[19],"to":[20,77,90],"the":[21,47,79,118,121,162,193],"regulatory":[22],"approval":[23],"of":[24,63,83,102,120,151,192,196],"ipilimumab":[25],"based":[26],"on":[27],"two":[28],"randomized":[29],"clinical":[30,100,190],"trials":[31],"overall":[33,132],"survival":[34],"advantage.":[35],"The":[36,131],"similarly":[37],"fully":[38],"human":[39],"anti-CTLA4":[40,142],"antibody":[41],"tremelimumab":[42,64,85,123,179],"had":[43],"been":[44],"developed":[45],"clinic":[48],"at":[49],"fixed":[51],"rate":[52],"infusion,":[53],"resulting":[54],"very":[56],"prolonged":[57],"infusion":[58,69,89,195],"times.":[59],"A":[60,72],"new":[61],"formulation":[62],"allowed":[65],"testing":[66,191],"shorter":[68],"time.":[70],"METHODS:":[71],"phase":[73],"1":[74],"multi-center":[75],"study":[76,171],"establish":[78],"safety":[80,176],"and":[81,99],"tolerability":[82],"administering":[84],"as":[86,182],"1-hour":[88,184,194],"melanoma.":[94],"Secondary":[95],"endpoints":[96],"included":[97],"pharmacokinetic":[98],"effects":[101],"tremelimumab.":[103,197],"RESULTS:":[104],"No":[105],"grade":[106],"3":[107],"or":[108,113],"greater":[109],"infusion-related":[110],"adverse":[111,115],"events":[112,116],"other":[114],"preventing":[117],"administration":[119],"full":[122],"dose":[124],"were":[125,147],"noted":[126,148],"44":[128],"treated":[129],"patients.":[130],"side":[133],"effect":[134],"profile":[135],"was":[136,180],"consistent":[137,160],"prior":[139,163],"experiences":[140],"antibodies.":[143,168],"Objective":[144],"11%":[150],"evaluable":[152],"is":[158],"also":[159],"experience":[164],"antagonistic":[167],"CONCLUSIONS:":[169],"This":[170],"did":[172],"not":[173],"identify":[174],"any":[175],"concerns":[177],"when":[178],"administered":[181],"infusion.":[185],"These":[186],"data":[187],"support":[188],"further":[189],"(Clinical":[198],"trial":[199],"registration":[200],"number":[201],"NCT00585000).":[202]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":7},{"year":2017,"cited_by_count":6},{"year":2016,"cited_by_count":3},{"year":2015,"cited_by_count":6},{"year":2014,"cited_by_count":4},{"year":2013,"cited_by_count":4}],"updated_date":"2026-11-10T11:39:43.021295","created_date":"2016-06-24T00:00:00"}